Vyvanse Should Not Be Used for PTSD Treatment
Vyvanse (lisdexamfetamine) is not approved for PTSD and should not be used for this indication. The FDA-approved indications for Vyvanse are limited to ADHD and binge eating disorder only 1. Current evidence-based guidelines explicitly recommend against using stimulants for PTSD treatment.
Guideline-Based Recommendations
The 2023 VA/DoD Clinical Practice Guideline for PTSD—the most authoritative and recent guideline—provides clear direction 2:
First-line treatments for PTSD are:
- Manualized psychotherapies (prolonged exposure, cognitive processing therapy, or EMDR) - these are preferred over all pharmacotherapy
- Pharmacotherapy when needed: paroxetine, sertraline, or venlafaxine (SSRIs/SNRIs)
The guideline makes strong recommendations against certain medications, though stimulants like Vyvanse are not specifically mentioned because they lack any evidence base for PTSD treatment 2.
Why Stimulants Are Not Appropriate
The FDA labeling for Vyvanse lists significant warnings that make it particularly problematic for PTSD patients 1:
- Psychiatric adverse reactions: Can exacerbate pre-existing psychosis, induce manic episodes, and cause new psychotic or manic symptoms
- Cardiovascular risks: Increases blood pressure and heart rate, with risk of sudden death in patients with cardiac abnormalities
- High abuse potential: PTSD patients often have comorbid substance use disorders, making stimulant use particularly risky
- Serotonin syndrome risk: When combined with SSRIs/SNRIs (the actual first-line PTSD medications), can cause life-threatening reactions
The Limited Anecdotal Evidence
While there are isolated case reports suggesting benefit 3, 4, these represent the lowest quality of evidence:
- One 2022 case report describes a single patient who subjectively reported improvement 3
- A 2000 case report similarly describes one individual 4
- These anecdotal observations cannot override FDA approval status, safety concerns, and guideline recommendations
The only controlled trial of lisdexamfetamine was for traumatic brain injury-related attention deficits, not PTSD 5. This is a completely different indication and population.
Evidence-Based Treatment Algorithm for PTSD
Step 1: Offer trauma-focused psychotherapy first (prolonged exposure, cognitive processing therapy, or EMDR) 2
Step 2: If psychotherapy is insufficient, unavailable, or declined, initiate pharmacotherapy with:
Step 3: For treatment-refractory cases, consider second- or third-line medications 6, 8
- These include other antidepressants or antipsychotics, not stimulants
Step 4: Consider combination psychotherapy plus pharmacotherapy for optimal outcomes 6
Critical Pitfalls to Avoid
- Do not prescribe stimulants off-label for PTSD symptoms - the risk-benefit ratio is unfavorable given lack of efficacy data and significant safety concerns
- Do not confuse comorbid ADHD with PTSD - if a patient has both conditions, treat each appropriately with evidence-based therapies for each specific diagnosis
- Do not rely on patient anecdotes about stimulants helping PTSD symptoms - this likely represents treatment of undiagnosed comorbid ADHD or placebo effect
- Avoid combining stimulants with SSRIs/SNRIs due to serotonin syndrome risk 1
If a patient with PTSD reports benefit from stimulants, reassess for comorbid ADHD, which affects 12-40% of PTSD patients and requires separate, appropriate treatment with stimulants for the ADHD component specifically—not for PTSD symptoms.